Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Current Oncology Reports
|
August 5, 2003
Vaccination strategies for lymphomas
Mohammed M Dar, Larry W Kwak
Nature Reviews. Cancer
|
January 26, 2007
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R Jackson, Denis R Patrick, Mohammed M Dar, et al.
Clinical Colorectal Cancer
|
May 26, 2011
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors
Trevor W Dennie, Ronald A Fleming, Carolyn J Bowen, et al.
Cancer
|
January 14, 2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
Ahmad A Tarhini, Michael Millward, Paul Mainwaring, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
April 4, 2013
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer
Yanli Deng, Caroline Sychterz, A Benjamin Suttle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
Thomas Yau, Pei-Jer Chen, Pierre Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer
Michael J Robertson, John M Kirkwood, Theodore F Logan, et al.
Clinical Pharmacology in Drug Development
|
May 4, 2016
Effect of lapatinib on oral digoxin absorption in patients
Kevin M Koch, Deborah A Smith, Jeff Botbyl, et al.
Cancer Chemotherapy and Pharmacology
|
May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
Kyle D Holen, Chandra P Belani, George Wilding, et al.
Cancer Chemotherapy and Pharmacology
|
January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
Elisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Current Oncology Reports
|
August 5, 2003
Vaccination strategies for lymphomas
Mohammed M Dar, Larry W Kwak
Nature Reviews. Cancer
|
January 26, 2007
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R Jackson, Denis R Patrick, Mohammed M Dar, et al.
Clinical Colorectal Cancer
|
May 26, 2011
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors
Trevor W Dennie, Ronald A Fleming, Carolyn J Bowen, et al.
Cancer
|
January 14, 2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
Ahmad A Tarhini, Michael Millward, Paul Mainwaring, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
April 4, 2013
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer
Yanli Deng, Caroline Sychterz, A Benjamin Suttle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
Thomas Yau, Pei-Jer Chen, Pierre Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer
Michael J Robertson, John M Kirkwood, Theodore F Logan, et al.
Clinical Pharmacology in Drug Development
|
May 4, 2016
Effect of lapatinib on oral digoxin absorption in patients
Kevin M Koch, Deborah A Smith, Jeff Botbyl, et al.
Cancer Chemotherapy and Pharmacology
|
May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
Kyle D Holen, Chandra P Belani, George Wilding, et al.
Cancer Chemotherapy and Pharmacology
|
January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
Elisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Page
of 2